| Symbol | TFB2M |
|---|---|
| Full Name | Mitochondrial Transcription Factor B2 |
| Chromosomal Location | 1p36.22 |
| NCBI Gene ID | [79657](https://www.ncbi.nlm.nih.gov/gene/79657) |
| Ensembl ID | [ENSG00000162836](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000162836) |
| UniProt | [Q9H0Y9](https://www.uniprot.org/uniprot/Q9H0Y9) |
TFB2M (Mitochondrial Transcription Factor B2) encodes a mitochondrial protein that functions as a transcription factor and methyltransferase essential for mitochondrial gene expression. Together with TFAM and TEFM, TFB2M promotes transcription initiation from mitochondrial DNA (mtDNA) promoters. Additionally, TFB2M possesses rRNA methyltransferase activity important for mitochondrial ribosome assembly[1].
The mitochondrial transcription machinery is essential for generating the 13 oxidative phosphorylation (OXPHOS) subunits encoded by mtDNA, as well as the rRNA and tRNA components required for mitochondrial translation. Proper mitochondrial gene expression is therefore critical for cellular energy production, and defects in this process are associated with neurodegenerative diseases including Alzheimer's Disease and Parkinson's Disease.
TFB2M is a mitochondrial protein with approximately 420 amino acids containing:
N-terminal Mitochondrial Targeting Sequence: A cleavable presequence (~30 amino acids) that directs the protein to the mitochondrial matrix
S-adenosylmethionine (SAM)-dependent methyltransferase domain: The core catalytic domain (~300 amino acids) containing motifs characteristic of methyltransferases
C-terminal domain: Involved in protein-protein interactions with other components of the transcription machinery
The protein shares structural homology with bacterial RNA methyltransferases but has evolved specialized functions in mitochondria.
TFB2M has two primary biochemical functions:
Mitochondrial Transcription Initiation:
rRNA Methyltransferase Activity:
The mitochondrial transcription machinery includes:
| Component | Function |
|---|---|
| TFAM | Mitochondrial transcription factor A; binds mtDNA promoters |
| TFB2M | Transcription factor B2; promotes initiation and has rRNA methyltransferase activity |
| TEFM | Mitochondrial transcription elongation factor; prevents premature termination |
| POLRMT | Mitochondrial RNA polymerase; catalytic subunit |
| mTERF1-4 | Mitochondrial transcription termination factors |
Human mitochondrial DNA is a circular genome (~16.5 kb) encoding:
The mtDNA has two main promoters:
TFB2M plays a critical role in regulating mitochondrial transcription:
TFB2M's rRNA methyltransferase activity is essential for mitochondrial translation:
Mitochondrial dysfunction is an early and prominent feature of Alzheimer's Disease pathogenesis[2]:
Mitochondrial Gene Expression Impairment:
Energy Failure:
Oxidative Stress:
Amyloid-beta Effects:
Parkinson's Disease shows strong mitochondrial involvement[3]:
Complex I Deficiency:
mtDNA Mutations:
Alpha-synuclein and Mitochondria:
LRRK2 and Mitochondria:
TFB2M mutations are associated with several mitochondrial disorders:
Mitochondrial Encephalomyopathy:
Leigh Syndrome:
Mitochondrial Myopathy:
TFB2M is expressed in all tissues with high metabolic demands:
Within the brain:
TFB2M localizes to:
Gene Therapy:
Small Molecule Modulators:
Mitochondrial Biogenesis:
Supportive Therapies:
TFB2M and related proteins may serve as:
Transcription Elongation: TEFM works with TFB2M to prevent transcription termination, critical for producing full-length transcripts[4].
Aging and mtDNA: Mitochondrial transcription declines with age, contributing to the age-related increase in neurodegenerative disease risk[5].
TFAM and Disease: TFAM mutations cause mitochondrial disease; TFB2M may have similar implications[6].
Translation Defects: Mutations in mitochondrial translation factors cause Leigh syndrome and other encephalopathies[7].
Falkenberg M, Larsson NG, Gustafsson CM. Mitochondrial transcription and translation. Annual Review of Biochemistry. 2002. ↩︎
Calvo SE, Mootha VK. Mitochondrial dysfunction in neurodegeneration. Annual Review of Neuroscience. 2017. ↩︎
Johri A, Beal MF. Mitochondrial dynamics in neurodegeneration. Trends in Pharmacological Sciences. 2018. ↩︎
Sorrentino V, Brunicardi FC, Liu Y, et al. Mitochondrial transcription termination factor 1 in disease. Frontiers in Cell and Developmental Biology. 2021. ↩︎
St John JC, Ramachandran J, Wu J, et al. Mitochondrial DNA, mitochondrial dysfunction, and neurodegeneration. Experimental Neurology. 2020. ↩︎
Gauthier LD, Zhang J, Lu K, et al. Mitochondrial transcription factor A (TFAM) in neurodegeneration. Neurobiology of Disease. 2019. ↩︎
McGowan A, Smeitink JA, Lightowlers RN, et al. Mitochondrial translation and disease. Brain. 2020. ↩︎